Paracetamol should be first-line therapy in osteoarthritis

Richard O Day and Garry G Graham
Med J Aust 2005; 182 (4): . || doi: 10.5694/j.1326-5377.2005.tb06657.x
Published online: 21 February 2005

Richard O Day,* Garry G Graham

  • Richard O Day
  • Garry G Graham

  • 1 University of New South Wales and St Vincent’s Hospital, Victoria Road, Darlinghurst, NSW 2010
  • 2 University of New South Wales, Sydney, NSW


Competing interests:

Professor Day is a member of advisory committees on COX-2 inhibitors for Merck Sharp & Dohme (Aust) Pty Ltd (which markets rofecoxib and etoricoxib), and previously for Pfizer Pty Ltd (which markets celecoxib). He is a member of a general advisory committee of GlaxoSmithKline (which markets paracetamol). GlaxoSmithKline have supported research projects of Professor Graham on paracetamol.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.